Replies to post #210075 on Biotech Values

[DewDiligence]

If I was invested in AZN, I would definitely be worried about MYSTIC...

On AZN’s 4Q16 CC, management received so many questions about MYSTIC that they pleaded with analysts to ask a non-MYSTIC question!

[genisi]

lower dose than for CTLA-4 in other tumor types

NSCLC patients for one, are weaker in terms of comorbidities and more prone to lung tox than melanoma patients so final CTLA-4 dose should be lower.

[DewDiligence]

For AZN, it’s MYSTIC or…cut bait:

http://uk.reuters.com/article/uk-astrazeneca-results-idUKKBN17T0PQ